Medpace Holdings, Inc. (MEDP) stock
MEDPNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 22, 2026Score 14/3046% above fair value
$646.87−6.22 (-0.95%)
Close on Nov 18, 2026Market cap $18.09BP/E 35.9Yield –
Medpace revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Medpace's revenue for the twelve months ending Sep 30, 2026 was $2.84B, up 20.4% year over year. For fiscal 2025 it was $2.53B, up 20.0% from the year before. Over ten years it grew 21.6% a year on average. The highest annual figure on record is $2.53B in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.53B | +20.0% |
| FY2024 | Dec 31, 2024 | $2.11B | +11.8% |
| FY2023 | Dec 31, 2023 | $1.89B | +29.2% |
| FY2022 | Dec 31, 2022 | $1.46B | +27.8% |
| FY2021 | Dec 31, 2021 | $1.14B | +23.4% |
| FY2020 | Dec 31, 2020 | $925.93M | +7.5% |
| FY2019 | Dec 31, 2019 | $860.97M | +22.2% |
| FY2018 | Dec 31, 2018 | $704.59M | +61.5% |
| FY2017 | Dec 31, 2017 | $436.15M | +3.5% |
| FY2016 | Dec 31, 2016 | $421.58M | +17.4% |
| FY2015 | Dec 31, 2015 | $359.06M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $716.00M | +8.5% |
| Q2 FY2026 | Jun 30, 2026 | $707.33M | +17.2% |
| Q1 FY2026 | Mar 31, 2026 | $706.60M | +26.5% |
| Q4 FY2025 | Dec 31, 2025 | $708.45M | +32.0% |
| Q3 FY2025 | Sep 30, 2025 | $659.90M | +23.7% |
| Q2 FY2025 | Jun 30, 2025 | $603.31M | +14.2% |
| Q1 FY2025 | Mar 31, 2025 | $558.57M | +9.3% |
| Q4 FY2024 | Dec 31, 2024 | $536.59M | +7.7% |
| Q3 FY2024 | Sep 30, 2024 | $533.32M | +8.3% |
| Q2 FY2024 | Jun 30, 2024 | $528.10M | +14.6% |
| Q1 FY2024 | Mar 31, 2024 | $511.04M | +17.7% |
| Q4 FY2023 | Dec 31, 2023 | $498.40M | +26.5% |
| Q3 FY2023 | Sep 30, 2023 | $492.50M | +28.3% |
| Q2 FY2023 | Jun 30, 2023 | $460.87M | +31.2% |
| Q1 FY2023 | Mar 31, 2023 | $434.07M | +31.2% |
| Q4 FY2022 | Dec 31, 2022 | $394.10M | +27.7% |
| Q3 FY2022 | Sep 30, 2022 | $383.74M | +29.8% |
| Q2 FY2022 | Jun 30, 2022 | $351.21M | +26.2% |
| Q1 FY2022 | Mar 31, 2022 | $330.95M | +27.3% |
| Q4 FY2021 | Dec 31, 2021 | $308.55M | +18.8% |
| Q3 FY2021 | Sep 30, 2021 | $295.57M | +28.3% |
| Q2 FY2021 | Jun 30, 2021 | $278.29M | +35.8% |
| Q1 FY2021 | Mar 31, 2021 | $259.97M | +12.6% |
| Q4 FY2020 | Dec 31, 2020 | $259.68M | +13.0% |
| Q3 FY2020 | Sep 30, 2020 | $230.37M | +6.5% |
| Q2 FY2020 | Jun 30, 2020 | $205.00M | -4.3% |
| Q1 FY2020 | Mar 31, 2020 | $230.88M | +15.0% |
| Q4 FY2019 | Dec 31, 2019 | $229.89M | +19.7% |
| Q3 FY2019 | Sep 30, 2019 | $216.24M | +20.6% |
| Q2 FY2019 | Jun 30, 2019 | $214.10M | +25.8% |
| Q1 FY2019 | Mar 31, 2019 | $200.74M | +23.1% |
| Q4 FY2018 | Dec 31, 2018 | $192.12M | +70.5% |
| Q3 FY2018 | Sep 30, 2018 | $179.25M | +62.0% |
| Q2 FY2018 | Jun 30, 2018 | $170.14M | +60.2% |
| Q1 FY2018 | Mar 31, 2018 | $163.08M | +53.0% |
| Q4 FY2017 | Dec 31, 2017 | $112.68M | +18.1% |
| Q3 FY2017 | Sep 30, 2017 | $110.64M | – |
| Q2 FY2017 | Jun 30, 2017 | $106.22M | – |
| Q1 FY2017 | Mar 31, 2017 | $106.61M | – |
| Q4 FY2016 | Dec 31, 2016 | $95.38M | – |
See a number that looks wrong?